Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by McGlashan, T. H. Articles by Breier, A. Search for Related Content PubMed Citation Articles by McGlashan, T. H. Articles by Breier, A. Atypical Neuroleptics Schizophrenia Spectrum Disorders Related Article

Randomized, Double-Blind Trial of Olanzapine Versus Placebo in Patients Prodromally Symptomatic for Psychosis

OBJECTIVE: This study assessed the efficacy of olanzapine in delaying or preventing conversion to psychosis and reducing symptoms in people with prodromal symptoms of schizophrenia. METHOD: This randomized trial occurred at four North American clinics in the Prevention Through Risk Identification, Management, and Education project. Outpatients received olanzapine (5–15 mg/day, N=31) or placebo (N=29) during a 1-year double-blind treatment period and no treatment during a 1-year follow-up period. Efficacy measures included the conversion-to-psychosis rate and Scale of Prodromal Symptoms scores. RESULTS: During the treatment year, 16.1% of olanzapine patients and 37.9% of placebo patients experienced a conversion to psychosis, a nearly significant difference. The hazard of conversion among placebo patients was about 2.5 times that among olanzapine-treated patients, which also approached significance. In the follow-up year, the conversion rate did not differ significantly between groups. During treatment, the mean score for prodromal positive symptoms improved more in the olanzapine group than in the placebo group, and the mixed-model repeated-measures least-squares mean score showed significantly greater improvement between weeks 8 and 28 with olanzapine. The olanzapine patients gained significantly more weight (mean=8.79 kg, SD=9.05, versus mean=0.30 kg, SD=4.24). CONCLUSIONS: A significant treatment difference in the conversion-to-psychosis rate was not demonstrated. However, these results may be influenced by low power. The nearly significant differences suggest that olanzapine might reduce the conversion rate and delay onset of psychosis. Olanzapine was efficacious for positive prodromal symptoms but induced weight gain. Further treatment research in this phase of illness is warranted.

Related Article:

In This Issue
Am J Psychiatry 2006 163: A64. [Full Text] [PDF]

This article has been cited by other articles:

				P. M. Thompson, G. Bartzokis, K. M. Hayashi, A. D. Klunder, P. H. Lu, N. Edwards, M. S. Hong, M. Yu, J. A. Geaga, A. W. Toga, et al. Time-Lapse Mapping of Cortical Changes in Schizophrenia with Different Treatments Cereb Cortex, May 1, 2009; 19(5): 1107 - 1123. [Abstract] [Full Text] [PDF]

				S. W. Woods, J. Addington, K. S. Cadenhead, T. D. Cannon, B. A. Cornblatt, R. Heinssen, D. O. Perkins, L. J. Seidman, M. T. Tsuang, E. F. Walker, et al. Validity of the Prodromal Risk Syndrome for First Psychosis: Findings From the North American Prodrome Longitudinal Study Schizophr Bull, April 21, 2009; (2009) sbp027v1. [Abstract] [Full Text] [PDF]

				T. Takahashi, S. J. Wood, A. R. Yung, B. Soulsby, P. D. McGorry, M. Suzuki, Y. Kawasaki, L. J. Phillips, D. Velakoulis, and C. Pantelis Progressive Gray Matter Reduction of the Superior Temporal Gyrus During Transition to Psychosis Arch Gen Psychiatry, April 1, 2009; 66(4): 366 - 376. [Abstract] [Full Text] [PDF]

				O. D. Howes, A. J. Montgomery, M.-C. Asselin, R. M. Murray, I. Valli, P. Tabraham, E. Bramon-Bosch, L. Valmaggia, L. Johns, M. Broome, et al. Elevated Striatal Dopamine Function Linked to Prodromal Signs of Schizophrenia Arch Gen Psychiatry, January 1, 2009; 66(1): 13 - 20. [Abstract] [Full Text] [PDF]

				U. Meyer, E. Spoerri, B. K. Yee, M. J. Schwarz, and J. Feldon Evaluating Early Preventive Antipsychotic and Antidepressant Drug Treatment in an Infection-Based Neurodevelopmental Mouse Model of Schizophrenia Schizophr Bull, October 8, 2008; (2008) sbn131v1. [Abstract] [Full Text] [PDF]

				F. Schultze-Lutter, S. Ruhrmann, J. Berning, W. Maier, and J. Klosterkotter Basic Symptoms and Ultrahigh Risk Criteria: Symptom Development in the Initial Prodromal State Schizophr Bull, June 25, 2008; (2008) sbn072v1. [Abstract] [Full Text] [PDF]

				S. J. Wood, C. Pantelis, D. Velakoulis, M. Yucel, A. Fornito, and P. D. McGorry Progressive Changes in the Development Toward Schizophrenia: Studies in Subjects at Increased Symptomatic Risk Schizophr Bull, March 1, 2008; 34(2): 322 - 329. [Abstract] [Full Text] [PDF]

				P. D. McGorry, A. R. Yung, A. Bechdolf, and P. Amminger Back to the Future: Predicting and Reshaping the Course of Psychotic Disorder Arch Gen Psychiatry, January 1, 2008; 65(1): 25 - 27. [Full Text] [PDF]

				T. D. Cannon, K. Cadenhead, B. Cornblatt, S. W. Woods, J. Addington, E. Walker, L. J. Seidman, D. Perkins, M. Tsuang, T. McGlashan, et al. Prediction of Psychosis in Youth at High Clinical Risk: A Multisite Longitudinal Study in North America Arch Gen Psychiatry, January 1, 2008; 65(1): 28 - 37. [Abstract] [Full Text] [PDF]

				A. R. YUNG and P. D. McGORRY Prediction of psychosis: setting the stage The British Journal of Psychiatry, December 1, 2007; 191(51): s1 - s8. [Abstract] [Full Text] [PDF]

				S. W. WOODS, E. M. TULLY, B. C. WALSH, K. A. HAWKINS, J. L. CALLAHAN, S. J. COHEN, D. H. MATHALON, T. J. MILLER, and T. H. McGLASHAN Aripiprazole in the treatment of the psychosis prodrome: An open-label pilot study The British Journal of Psychiatry, December 1, 2007; 191(51): s96 - s101. [Abstract] [Full Text] [PDF]

				R. E. HOFFMAN, S. W. WOODS, K. A. HAWKINS, B. PITTMAN, M. TOHEN, A. PREDA, A. BREIER, J. GLIST, J. ADDINGTON, D. O. PERKINS, et al. Extracting spurious messages from noise and risk of schizophrenia-spectrum disorders in a prodromal population The British Journal of Psychiatry, October 1, 2007; 191(4): 355 - 356. [Abstract] [Full Text] [PDF]

				R. E. Hoffman A Social Deafferentation Hypothesis for Induction of Active Schizophrenia Schizophr Bull, September 1, 2007; 33(5): 1066 - 1070. [Abstract] [Full Text] [PDF]

				T. H. McGlashan, J. Addington, T. Cannon, M. Heinimaa, P. McGorry, M. O'Brien, D. Penn, D. Perkins, R. K. R. Salokangas, B. Walsh, et al. Recruitment and Treatment Practices for Help-Seeking "Prodromal" Patients Schizophr Bull, May 4, 2007; (2007) sbm025v1. [Abstract] [Full Text] [PDF]

				A. P. Morrison, P. French, S. Parker, M. Roberts, H. Stevens, R. P. Bentall, and S. W. Lewis Three-Year Follow-up of a Randomized Controlled Trial of Cognitive Therapy for the Prevention of Psychosis in People at Ultrahigh Risk Schizophr Bull, May 1, 2007; 33(3): 682 - 687. [Abstract] [Full Text] [PDF]

				T. D. Cannon, B. Cornblatt, and P. McGorry Editor's Introduction: The Empirical Status of the Ultra High-Risk (Prodromal) Research Paradigm Schizophr Bull, May 1, 2007; 33(3): 661 - 664. [Abstract] [Full Text] [PDF]

				D. Gothelf, C. Feinstein, T. Thompson, E. Gu, L. Penniman, E. Van Stone, H. Kwon, S. Eliez, and A. L. Reiss Risk Factors for the Emergence of Psychotic Disorders in Adolescents With 22q11.2 Deletion Syndrome Am J Psychiatry, April 1, 2007; 164(4): 663 - 669. [Abstract] [Full Text] [PDF]

				J. J. BLOCK Ethical Concerns Regarding Olanzapine Versus Placebo in Patients Prodromally Symptomatic for Psychosis Am J Psychiatry, October 1, 2006; 163(10): 1838 - 1838. [Full Text] [PDF]

				D. Kingdon Psychological and social interventions for schizophrenia BMJ, July 29, 2006; 333(7561): 212 - 213. [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2006 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us